Cryoport director granted stock and options

Cryoport, Inc. director Daniel M. Hancock reported equity awards consisting of restricted stock and stock options.

Rhea-AI Filing Summary

Cryoport, Inc. director Daniel M. Hancock reported equity awards consisting of restricted stock and stock options. He received 10,350 restricted stock rights that vest in full on June 5, 2027 and will convert into the same number of common shares when vested.

He was also granted options to buy 16,077 shares of common stock at an exercise price of $15.70 per share, expiring on June 5, 2033. One-twelfth of these options vest monthly on the 5th, starting July 5, 2026. Following the grants, he directly holds 69,052 common shares.

Insider Trade Summary

Grant/Award: 26,427 shares

Grant/Award 2 txns

Insider HANCOCK DANIEL M

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Option (Right to Buy Common Stock)	16,077	$0.00	$0.00
Grant/Award	Common Stock	10,350	$0.00	$0.00

Holdings After Transaction: Option (Right to Buy Common Stock) — 16,077 contracts (Direct); Common Stock — 69,052 shares (Direct)

Footnotes (2)

1. F1. Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis.
2. F2. 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026.

Key Figures

Restricted stock rights granted: 10,350 rights Options granted: 16,077 options Option exercise price: $15.70 per share +4 more

7 metrics

Restricted stock rights granted 10,350 rights Grant on June 5, 2026; vest in full June 5, 2027

Options granted 16,077 options Right to buy common stock, granted June 5, 2026

Option exercise price $15.70 per share Exercise price for 16,077 stock options

Option expiration date June 5, 2033 Expiration for granted stock options

Director share holdings 69,052 shares Common shares directly held after reported transactions

RSU vesting date June 5, 2027 Restricted stock rights vest and convert one-for-one

Option vesting schedule 1/12 monthly Vests on 5th of month for 12 months from July 5, 2026

Key Terms

restricted stock rights, Option (Right to Buy Common Stock), exercise price, vesting

4 terms

restricted stock rights financial

"Reflects grant of restricted stock rights that vest in full on June 5, 2027"

Restricted stock rights are ownership claims in company shares that come with limits on when or how they can be sold or transferred, often tied to time-based or performance conditions. For investors, these rights matter because they affect when insiders truly own or can monetize shares — influencing future share supply, executive incentives, and potential stock price pressure much like a savings account that only becomes withdrawable after meeting set conditions.

Option (Right to Buy Common Stock) financial

"security_title: Option (Right to Buy Common Stock) with 16,077 shares"

exercise price financial

"Options have a conversion or exercise price of 15.7000 per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vesting financial

"1/12th of the options vest on the 5th of the month for twelve months"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Cryoport (CYRX) director Daniel Hancock report in this Form 4?

Director Daniel M. Hancock reported receiving equity compensation awards. He was granted 10,350 restricted stock rights and 16,077 stock options, both tied to Cryoport common stock, with specific vesting schedules and no open-market buying or selling reported in this filing.

How many Cryoport (CYRX) restricted stock rights were granted to Daniel Hancock?

Daniel Hancock received 10,350 restricted stock rights. These awards vest in full on June 5, 2027 and then automatically convert into an equal number of Cryoport common shares on a one-for-one basis, reflecting time-based compensation rather than a market purchase.

What are the terms of Daniel Hancock’s Cryoport (CYRX) stock option grant?

He was granted options covering 16,077 shares of Cryoport common stock at an exercise price of $15.70 per share. The options expire on June 5, 2033, with one-twelfth of the grant vesting monthly on the 5th, beginning July 5, 2026.

Did Daniel Hancock buy or sell Cryoport (CYRX) shares in the market?

The Form 4 shows no open-market buys or sells. Instead, it reports equity compensation: restricted stock rights and stock options granted at no cost, with future vesting and, for the options, a fixed $15.70 exercise price per share.

How many Cryoport (CYRX) shares does Daniel Hancock hold after these grants?

After the reported equity awards, Daniel Hancock directly holds 69,052 shares of Cryoport common stock. In addition, he holds stock options for 16,077 underlying shares, which become exercisable over time according to the disclosed vesting schedule.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/08/2026 - 09:09 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HANCOCK DANIEL M

(Last) (First) (Middle)

C/O CRYOPORT INC.

112 WESTWOOD PLACE, SUITE 350

(Street)

BRENTWOOD TENNESSEE 37027

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Cryoport, Inc. [ CYRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	06/05/2026		A		10,350	A	$0(1)	69,052	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Option (Right to Buy Common Stock)	$15.7	06/05/2026		A		16,077		(2)	06/05/2033	Common Stock	16,077	$0	16,077	D

Explanation of Responses:

1. Reflects grant of restricted stock rights that vest in full on June 5, 2027, and upon vesting automatically convert to shares of common stock on a one-for-one basis.

2. 1/12th of the options vest on the 5th of the month for twelve months beginning July 5, 2026.

	/s/ Daniel M. Hancock	06/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)